Immunitybio Inc (IBRX) Stock Analysis
Verdict: WATCH (do not buy)
ANKTIVA's rapid commercial ramp is offset by high cash burn, negative equity, and dilution risk before its January 2027 PDUFA date.
Investment score: 45/100
Analysis as of
Is Immunitybio Inc stock worth reviewing? AI model thesis
The model sees strong commercial traction for ANKTIVA (+92% YoY product revenue to $50.7M in Q2 2026), but high quarterly cash burn (-$147.15M FCF) and negative equity (-$1.05B) create severe dilution overhang.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 35/100 (weight 15%)
- Technical Momentum: 70/100 (weight 15%)
- Earnings Quality: 50/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Immunitybio Inc opportunities and risks
What speaks for IBRX
- ANKTIVA commercial revenue acceleration
What speaks against IBRX
- Severe quarterly cash burn and short runway
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| IBRX | n/a | 63.4x | n/a | 94.6% | -598.6% | -2.7% |
| SMMT | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.4% |
| BMRN | 145.1x | 3.1x | 36.3x | 75.5% | 2.1% | 6.9% |
| PCVX | n/a | 0.0x | n/a | 0.0% | 0.0% | -11.6% |
| MDGL | n/a | 8.3x | n/a | 91.5% | -25.3% | -1.9% |
| KRYS | 40.0x | 22.2x | 42.6x | 93.3% | 54.8% | 2.6% |
| Peer median | n/a | 3.1x | n/a | 75.5% | 0.0% | -1.9% |
Frequently asked questions about Immunitybio Inc (IBRX)
Is IBRX stock a good investment?
The cached TradeMates AI model rates Immunitybio Inc as WATCH (do not buy) with an investment score of 45/100. The model sees strong commercial traction for ANKTIVA (+92% YoY product revenue to $50.7M in Q2 2026), but high quarterly cash burn (-$147.15M FCF) and negative equity (-$1.05B) create severe dilution overhang. This is algorithmic model output, not personal investment advice.
Is IBRX stock a buy?
The TradeMates model verdict for IBRX is WATCH (do not buy) with an investment score of 45/100. Treat this as a model signal to review, not a personal buy recommendation.